131 related articles for article (PubMed ID: 9242539)
1. HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells.
Mutis T; Schrama E; van Luxemburg-Heijs SA; Falkenburg JH; Melief CJ; Goulmy E
Blood; 1997 Aug; 90(3):1083-90. PubMed ID: 9242539
[TBL] [Abstract][Full Text] [Related]
2. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
3. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
[TBL] [Abstract][Full Text] [Related]
4. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-.
Blair A; Hogge DE; Sutherland HJ
Blood; 1998 Dec; 92(11):4325-35. PubMed ID: 9834239
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E
Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944
[TBL] [Abstract][Full Text] [Related]
6. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia.
van der Hoorn MA; van Luxemburg-Heijs SA; van Bergen CA; Bongaerts R; Willemze R; Falkenburg JH
Methods; 2003 Oct; 31(2):113-9. PubMed ID: 12957568
[TBL] [Abstract][Full Text] [Related]
7. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.
Griffioen M; van der Meijden ED; Slager EH; Honders MW; Rutten CE; van Luxemburg-Heijs SA; von dem Borne PA; van Rood JJ; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3837-42. PubMed ID: 18316730
[TBL] [Abstract][Full Text] [Related]
8. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
Mutis T; Schrama E; Melief CJ; Goulmy E
Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
[TBL] [Abstract][Full Text] [Related]
9. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.
Fujii S; Fujimoto K; Shimizu K; Ezaki T; Kawano F; Takatsuki K; Kawakita M; Matsuno K
Cancer Res; 1999 May; 59(9):2150-8. PubMed ID: 10232602
[TBL] [Abstract][Full Text] [Related]
10. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells.
Dolstra H; Fredrix H; van der Meer A; de Witte T; Figdor C; van de Wiel-van Kemenade E
Bone Marrow Transplant; 2001 May; 27(10):1087-93. PubMed ID: 11438826
[TBL] [Abstract][Full Text] [Related]
11. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities.
Costello RT; Mallet F; Gaugler B; Sainty D; Arnoulet C; Gastaut JA; Olive D
Cancer Res; 2000 Aug; 60(16):4403-11. PubMed ID: 10969785
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus infection abrogates the stimulatory capacity of B cells to a major histocompatibility complex class-II-restricted proliferative T-cell clone.
van Lochem EG; Bakker A; Snijder S; Aarts M; de Gast GC; Goulmy E
Hum Immunol; 1995 Feb; 42(2):137-44. PubMed ID: 7744617
[TBL] [Abstract][Full Text] [Related]
13. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
[TBL] [Abstract][Full Text] [Related]
14. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
15. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia.
Nakao S; Takami A; Takamatsu H; Zeng W; Sugimori N; Yamazaki H; Miura Y; Ueda M; Shiobara S; Yoshioka T; Kaneshige T; Yasukawa M; Matsuda T
Blood; 1997 May; 89(10):3691-9. PubMed ID: 9160674
[TBL] [Abstract][Full Text] [Related]
16. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.
Norde WJ; Overes IM; Maas F; Fredrix H; Vos JC; Kester MG; van der Voort R; Jedema I; Falkenburg JH; Schattenberg AV; de Witte TM; Dolstra H
Blood; 2009 Mar; 113(10):2312-23. PubMed ID: 19074734
[TBL] [Abstract][Full Text] [Related]
17. Cross-protective murine graft-versus-leukemia responses to phenotypically distinct myeloid leukemia lines.
Patterson AE; Korngold R
Biol Blood Marrow Transplant; 2000; 6(5A):537-47. PubMed ID: 11071259
[TBL] [Abstract][Full Text] [Related]
18. [Expression of AC133 vs. CD34 in acute childhood leukemias].
Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
[TBL] [Abstract][Full Text] [Related]
19. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen.
Jiang YZ; Mavroudis D; Dermime S; Hensel N; Couriel D; Molldrem J; Barrett AJ
Br J Haematol; 1996 Jun; 93(3):606-12. PubMed ID: 8652381
[TBL] [Abstract][Full Text] [Related]
20. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
